Dr Matasar on the Design of the OLYMPIA-3 Trial in DLBCL
Matthew Matasar, MD, discusses the design of the phase 3 OLYMPIA-3 trial of odronextamab plus CHOP in treatment-naive intermediate- or high-risk DLBCL.
Source: onclive.com
Matthew Matasar News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Matthew Matasar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Matthew Matasar Today - Breaking & Trending Today
RUTGERS CANCER INSTITUTE OF NEW JERSEY AND ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL'S TRANSPLANT AND CELL THERAPY PROGRAM AWARDED ACCREDITATION BY THE FOUNDATION FOR THE ACCREDITATION OF CELLULAR THERAPY
The Foundation for the Accreditation of Cellular Therapy (FACT) has once again awarded Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University
Source: newswise.com
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital's Transplant and Cell Therapy
The Foundation for the Accreditation of Cellular Therapy (FACT) has once again awarded Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University
Source: newswise.com
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Expansive Portfolio of Hematology/Oncology Data at the 65th American Society of Hematology Annual Meeting and Exposition
Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present an extensive array of hematology/oncology data from their clinical research program at the 65th American Society of Hematology Annual Meeting and Exposition, being held in San Diego, California from December 9-12, 2023.
Source: onclive.com
Rutgers Research Summit Aims to Broaden Oncologic Perspectives Across New Jersey
Andrew Evens, DO, MBA, MSc, highlights key points presented during the 2023 Rutgers Cancer Institute of New Jersey’s Annual Oncology Clinical Practice and Research Summit, the clinical implications of these presentations, and lymphoma treatment innovations that Rutgers Cancer Institute is providing to patients throughout New Jersey.
Source: onclive.com